Nuwellis (NUWE) investor relations material

Executive summary

• Q1 2026 marked a shift from strategic reset to execution, with strengthened leadership, capital foundation, and the acquisition of Rendiatech, enhancing the product portfolio with automated kidney-function monitoring.

• Focused on operational discipline, market coverage expansion, and validation of pediatrics as a growth category, with pediatrics now representing about 50% of U.S. revenue.

• Enhanced board and field leadership, including new CFO, Director of Clinical Strategy, and experienced sales leaders.

• Expanded commercial coverage with new territories and received new U.S. patents for pediatric and ultrafiltration technologies.

Financial highlights

• Revenue for Q1 2026 was $2.4 million, up 26% year-over-year from $1.9 million.

• Gross margin improved to 70.1%, a 14% increase year-over-year, driven by pricing, product mix, and contract manufacturing.

• Operating expenses rose to $6 million from $4.1 million, reflecting higher sales headcount and compensation.

• Net loss attributable to common shareholders was $4.3 million for Q1 2026.

• Cash and restricted cash equivalents were $2.2 million as of March 31, 2026, with no debt.

Outlook and guidance

• Developing a plan to reduce monthly cash burn by approximately 50% by Q4 2026.

• Continued focus on disciplined capital allocation, gross margin consistency, and commercial execution.

• New product from Rendiatech acquisition expected to launch in the U.S. in 2027.

• Management highlights a more focused and commercially disciplined organization, with a foundation in Aquadex, growth in pediatrics, and a broader cardiorenal strategy.

• Forward-looking statements emphasize anticipated growth in 2026 and beyond, but caution about risks related to commercialization, funding, and integration of acquisitions.